IGF1R c.3179G>A (E1013E)

IGF1R c.3179G>A — The Receptor Variant That May Help You Live Longer

Of all the genetic pathways linked to longevity, the insulin/IGF-1 signaling (IIS) pathway |
The IIS pathway coordinates growth, metabolism, and stress response across almost all animals.
When signaling is reduced, cells shift from growth mode into maintenance and repair mode,
which appears to extend lifespan in every organism tested from yeast to primates
is the most replicated. This variant in IGF1R — the gene encoding the insulin-like growth factor 1
receptor — sits at the very hub of that pathway. It is a synonymous variant, meaning the DNA
change does not alter the protein sequence. Yet despite this "silent" appearance, carriers of
the A allele consistently show lower circulating IGF-1 levels and are overrepresented among
people who live the longest.

The Mechanism

The variant is a G-to-A change at position 3179 of the IGF1R coding sequence, within exon 16.
Both the G and A versions of codon 1013 encode the same amino acid (glutamic acid), which is
why this is classified as synonymous. So why does it matter?

Synonymous mutations can powerfully affect gene function | So-called "silent" mutations
can alter mRNA secondary structure, disrupt exonic splicing enhancers or silencers,
change codon usage (affecting translation speed and protein folding), and alter mRNA
stability — none of which are detectable at the amino acid level through several
mechanisms not visible at the protein level. For rs2229765, the predominant hypothesis
is that the G-to-A change disrupts an exonic splicing enhancer | ESEs are short
sequences within exons recognized by SR proteins. They promote inclusion of the
surrounding exon in the final mRNA. Disrupting an ESE can cause exon skipping, leading
to a shorter, sometimes less functional receptor protein, shifting the balance of
IGF1R mRNA splice isoforms. The result appears to be subtly reduced functional receptor
at the cell surface, which in turn leads to lower circulating free IGF-1 (since IGF-1
in the bloodstream is partly regulated by its receptor's clearance and feedback activity).

The Evidence

The foundational human study came from Bonafe et al. in 2003 | Bonafe M et al.
Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide
3-kinase genes affect IGF-I plasma levels and human longevity. J Clin Endocrinol Metab,
2003. In an Italian population study comparing
278 young-to-middle-aged adults (17-85 years) with 218 very long-lived individuals (86-109
years), carriers of the A allele had lower free plasma IGF-1 levels and were significantly
more common among the oldest group.

The TRELONG (Treviso Longeva) study confirmed and extended this in a larger, longitudinal
Italian cohort of 668 subjects aged 70-106. Albani et al. 2009 | Albani D et al. A
polymorphic variant of the insulin-like growth factor 1 (IGF-1) receptor correlates with
male longevity in the Italian population. BMC Geriatrics, 2009
found a sex-specific pattern: in men, the A allele frequency increased from 34.4% in the
70-85 age group to 43.7% among those 85 and older (p=0.04). Men with the AA genotype had
the lowest IGF-1 levels in the oldest cohort (mean 119 ± 50 ng/mL, versus 185 ± 74 ng/mL
in GG men). A subsequent prospective follow-up of this cohort Albani et al. 2011 | Albani D
et al. Insulin-like growth factor 1 receptor polymorphism rs2229765 and circulating
interleukin-6 level affect male longevity in a population-based prospective study.
Aging Male, 2011 found that AA males had
a 76% reduced mortality risk compared to GG males (OR 0.24, 95% CI 0.07-0.64, p=0.008).
The effect was not replicated in women, suggesting sex-specific biology in IIS pathway
regulation of aging.

A gene combination study Barbieri et al. 2012 | Barbieri M et al. A/Asp/Val allele combination
of IGF1R, IRS2, and UCP2 genes is associated with better metabolic profile, preserved
energy expenditure parameters, and low mortality rate in longevity. Age (Dordr),
2012 found that the A allele of IGF1R combined
with specific variants in IRS2 (Asp allele) and UCP2 (Val allele) was associated with a
3.2-fold increased probability of reaching extreme old age (OR 3.185, 95% CI 1.63-6.19,
p=0.0006) in 722 Italian subjects. This combination was also associated with lower insulin
resistance, preserved resting metabolic rate, and better energy expenditure parameters.

A meta-analysis of four studies | Di Bona D et al. Association between genetic
variations in the insulin/insulin-like growth factor (IGF-1) signaling pathway and longevity:
a systematic review and meta-analysis. Curr Vasc Pharmacol, 2014
found that across available data, subjects carrying the A allele of rs2229765 had a
significantly greater probability of longevity. Evidence level is moderate: findings
are replicated across multiple Italian cohorts, but populations studied are geographically
limited and sex-specific effects complicate interpretation.

Practical Implications

This variant acts through reduced IIS signaling. The same pathway is modified by protein
intake (protein directly raises IGF-1 levels), periodic fasting, and dietary patterns.
Carriers of the A allele who wish to leverage the IGF-1-lowering benefit that appears
genetically advantageous can amplify it through targeted dietary choices — primarily
moderating protein intake during midlife. The key evidence base here comes from studies
showing protein restriction substantially reduces IGF-1 in humans, with most longevity
benefit concentrated in the 50-65 age range for moderate protein reduction.

Monitoring serum IGF-1 allows calibration of diet and lifestyle interventions. Total
IGF-1 of 100-175 ng/mL in adults is generally associated with the longevity range,
while levels above 200 ng/mL have been linked to increased cancer risk in multiple
epidemiological studies.

Interactions

The strongest documented interaction is with IRS2 (rs1805097, the Asp/Gly variant)
and UCP2 (rs659366, the Val/Ala variant). When all three genes carry their "longevity"
alleles (IGF1R-A, IRS2-Asp, UCP2-Val), the longevity association is dramatically
amplified (OR 3.185 vs ~1.3 for any single variant alone). This reflects the IIS
pathway's interconnected nature: IGF1R sits upstream, IRS2 is the intracellular docking
protein it signals through, and UCP2 modulates the mitochondrial energy dissipation
that determines how cells respond to reduced IIS signaling. Variants in PI3K pathway
genes that work downstream of IGF1R may further modify this effect.

IGF-1 levels are also influenced by variants in the IGF1 gene itself (particularly
rs35767 in the promoter region, which affects IGF-1 transcription). Carrying the
IGF1R A allele alongside IGF1 promoter variants that reduce IGF-1 production could
compound the IIS reduction further.